Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2025; 17(1): 98433
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.98433
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.98433
Complete response of gallbladder cancer treated with gemcitabine and cisplatin chemotherapy combined with durvalumab: A case report and review of literature
Kai Chen, Xu Feng, Yuan Shi, Xin-Lin Li, Zheng-Rong Shi, Xiang Lan, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Author contributions: Chen K conducted the literature review and contributed to manuscript drafting and data interpretation; Feng X collected all clinical data and evaluated the examination results; Shi Y assisted in data collection and analysis; Li XL was responsible for revising the manuscript for important intellectual content; Shi ZR contributed to the study design and methodology; Lan X served as the corresponding author, overseeing the overall direction and final approval of the manuscript for submission and publication.
Supported by General Project of Natural Science Foundation of Chongqing, China, No. cstc2021jcyj-msxmX0604; and Chongqing Doctoral "Through Train" Research Program, China, No. CSTB2022BSXM-JCX0045.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiang Lan, PhD, Chief Doctor, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Youyi Road, Yuzhong District, Chongqing 400016, China. lanxiang_tmmu@163.com
Received: June 26, 2024
Revised: October 10, 2024
Accepted: November 4, 2024
Published online: January 15, 2025
Processing time: 169 Days and 5.8 Hours
Revised: October 10, 2024
Accepted: November 4, 2024
Published online: January 15, 2025
Processing time: 169 Days and 5.8 Hours
Core Tip
Core Tip: This study presents a significant case of a patient with locally advanced gallbladder cancer (GBC) who achieved a clinical complete response following treatment with a novel regimen combining gemcitabine, cisplatin, and durvalumab (GC-D). Despite the notorious resistance of GBC to conventional therapies, the positive outcomes observed in this case suggest potential benefits of immunotherapy in this context. These findings highlight the need for further research to validate the efficacy of the GC-D regimen and to explore its implications for future treatment protocols in GBC.